Ra Pharmaceuticals (RARX) Given New $0.00 Price Target at BMO Capital Markets
A number of other equities analysts have also recently weighed in on RARX. Jefferies Group set a $25.00 price target on shares of Ra Pharmaceuticals and gave the stock a buy rating in a research report on Friday, August 25th. Zacks Investment Research raised shares of Ra Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, September 26th. Royal Bank Of Canada began coverage on shares of Ra Pharmaceuticals in a research report on Thursday, September 14th. They set an outperform rating and a $21.00 price target on the stock. Finally, Credit Suisse Group lifted their price target on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the stock an outperform rating in a research report on Friday, November 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $23.20.
Shares of Ra Pharmaceuticals (NASDAQ RARX) traded down $0.95 during mid-day trading on Tuesday, reaching $7.97. 1,110,800 shares of the company’s stock were exchanged, compared to its average volume of 131,548. Ra Pharmaceuticals has a 1 year low of $7.86 and a 1 year high of $27.84.
Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06). equities research analysts predict that Ra Pharmaceuticals will post -2.46 EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in RARX. Tekla Capital Management LLC bought a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $7,418,000. Citadel Advisors LLC bought a new stake in Ra Pharmaceuticals in the 3rd quarter valued at $4,664,000. Numeric Investors LLC bought a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $2,484,000. Nexthera Capital LP bought a new stake in Ra Pharmaceuticals in the 2nd quarter valued at $1,912,000. Finally, Sectoral Asset Management Inc lifted its position in Ra Pharmaceuticals by 55.6% in the 3rd quarter. Sectoral Asset Management Inc now owns 278,082 shares of the company’s stock valued at $4,060,000 after acquiring an additional 99,332 shares in the last quarter. 69.64% of the stock is currently owned by institutional investors.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.